Horst Schran
Impact in
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Transplantation top 2%
- Renal Transplantation Outcomes and Treatments
Papers in
- Hematology 26
- Chronic Myeloid Leukemia Treatments 19
-
- Renal Transplantation Outcomes and Treatments 6
- Co-authors
- Bin PengPeter LloydOphelia YinAndrej SkerjanecChristina RaveraTianling ChenJames R. BerensonJohn J. Seaman
- Journals
- The Journal of Clinical Pharmacology (12 papers)Journal of Clinical Oncology (7 papers)Clinical Pharmacology & Therapeutics (5 papers)Blood (5 papers)Biopharmaceutics & Drug Disposition (2 papers)
- Partner nations
- United StatesSwitzerlandJapan
In The Last Decade
Horst Schran
69 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Hematology 898
- Transplantation 179
- Genetics 617
- Oncology 1.1k
- Gastroenterology 141
Countries citing papers authored by Horst Schran
This map shows the geographic impact of Horst Schran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Horst Schran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Horst Schran more than expected).
Fields of papers citing papers by Horst Schran
This network shows the impact of papers produced by Horst Schran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Horst Schran. The network helps show where Horst Schran may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Horst Schran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 4 | |
| 2 | 2010 | 17 | |
| 3 | 2009 | 126 | |
| 4 | 2008 | 8 | |
| 5 | 2008 | 41 | |
| 6 | 2008 | 132 | |
| 7 | 2007 | 115 | |
| 8 | 2005 | 55 | |
| 9 | Clinical Pharmacokinetics of Imatinib Hit paper breakdown → | 2005 | 513 |
| 10 | 2004 | 45 | |
| 11 | No evidence for an adverse interaction between zoledronic acid and thalidomide Preliminary safety analysis from the Australasian leukaemia and lymphoma group MM6 Myeloma Trial | 2003 | 2 |
| 12 | 2003 | 177 | |
| 13 | 2002 | 310 | |
| 14 | 2000 | 56 | |
| 15 | 1996 | 31 | |
| 16 | 1996 | 27 | |
| 17 | 1995 | 205 | |
| 18 | 1994 | 5 | |
| 19 | 1991 | 16 | |
| 20 | 1988 | 16 |
About Horst Schran
Horst Schran is a scholar working on Hematology, Transplantation, Genetics, Oncology and Pharmacology, having authored 70 papers that have together received 3.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (19 papers), Chronic Lymphocytic Leukemia Research (17 papers), Bone health and treatments (10 papers), Cancer Treatment and Pharmacology (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers), Pharmacological Effects and Toxicity Studies (7 papers), Renal Transplantation Outcomes and Treatments (6 papers) and Pituitary Gland Disorders and Treatments (5 papers). The work is most often cited by research in Hematology (898 citations), Transplantation (179 citations), Genetics (617 citations), Oncology (1.1k citations) and Gastroenterology (141 citations). Horst Schran has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Bin Peng, Peter Lloyd, Ophelia Yin, Andrej Skerjanec, Christina Ravera, Tianling Chen, James R. Berenson, John J. Seaman, Wei Zhou and Venkat Sethuraman. Their work appears in journals such as The Journal of Clinical Pharmacology, Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, Blood and Biopharmaceutics & Drug Disposition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.